Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemia

The detection of minimal residual disease (MRD) is an important prognostic factor in childhood acute lymphoblastic leukemia (ALL) providing crucial information on the response to treatment and risk of relapse. However, the high cost of these techniques restricts their use in countries with limited resources. Thus, we prospectively studied the use of flow cytometry (FC) with a simplified 3-color assay and a limited antibody panel to detect MRD in the bone marrow (BM) and peripheral blood (PB) of children with ALL. BM and PB samples from 40 children with ALL were analyzed on days (d) 14 and 28 during induction and in weeks 24-30 of maintenance therapy. Detectable MRD was defined as > 0.01% cells expressing the aberrant immunophenotype as characterized at diagnosis among total events in the sample. A total of 87% of the patients had an aberrant immunophenotype at diagnosis. On d14, 56% of the BM and 43% of the PB samples had detectable MRD. On d28, this decreased to 45% and 31%, respectively. The percentage of cells with the aberrant phenotype was similar in both BM and PB in T-ALL but about 10 times higher in the BM of patients with B-cell-precursor ALL. Moreover, MRD was detected in the BM of patients in complete morphological remission (44% on d14 and 39% on d28). MRD was not significantly associated to gender, age, initial white blood cell count or cell lineage. This FC assay is feasible, affordable and readily applicable to detect MRD in centers with limited resources.

Saved in:
Bibliographic Details
Main Authors: Delbuono,Elizabete, Maekawa,Yumi H., Latorre,Maria do Rosário D. O., Seber,Adriana, Petrilli,Antonio Sergio, Braga,Josefina A. P., Lee,Maria Lúcia M.
Format: Digital revista
Language:English
Published: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular 2008
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842008000400010
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1516-84842008000400010
record_format ojs
spelling oai:scielo:S1516-848420080004000102008-10-28Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemiaDelbuono,ElizabeteMaekawa,Yumi H.Latorre,Maria do Rosário D. O.Seber,AdrianaPetrilli,Antonio SergioBraga,Josefina A. P.Lee,Maria Lúcia M. Minimal residual disease acute lymphoblastic leukemia flow cytometry children peripheral blood The detection of minimal residual disease (MRD) is an important prognostic factor in childhood acute lymphoblastic leukemia (ALL) providing crucial information on the response to treatment and risk of relapse. However, the high cost of these techniques restricts their use in countries with limited resources. Thus, we prospectively studied the use of flow cytometry (FC) with a simplified 3-color assay and a limited antibody panel to detect MRD in the bone marrow (BM) and peripheral blood (PB) of children with ALL. BM and PB samples from 40 children with ALL were analyzed on days (d) 14 and 28 during induction and in weeks 24-30 of maintenance therapy. Detectable MRD was defined as > 0.01% cells expressing the aberrant immunophenotype as characterized at diagnosis among total events in the sample. A total of 87% of the patients had an aberrant immunophenotype at diagnosis. On d14, 56% of the BM and 43% of the PB samples had detectable MRD. On d28, this decreased to 45% and 31%, respectively. The percentage of cells with the aberrant phenotype was similar in both BM and PB in T-ALL but about 10 times higher in the BM of patients with B-cell-precursor ALL. Moreover, MRD was detected in the BM of patients in complete morphological remission (44% on d14 and 39% on d28). MRD was not significantly associated to gender, age, initial white blood cell count or cell lineage. This FC assay is feasible, affordable and readily applicable to detect MRD in centers with limited resources.info:eu-repo/semantics/openAccessAssociação Brasileira de Hematologia e Hemoterapia e Terapia CelularRevista Brasileira de Hematologia e Hemoterapia v.30 n.4 20082008-08-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842008000400010en10.1590/S1516-84842008000400010
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Delbuono,Elizabete
Maekawa,Yumi H.
Latorre,Maria do Rosário D. O.
Seber,Adriana
Petrilli,Antonio Sergio
Braga,Josefina A. P.
Lee,Maria Lúcia M.
spellingShingle Delbuono,Elizabete
Maekawa,Yumi H.
Latorre,Maria do Rosário D. O.
Seber,Adriana
Petrilli,Antonio Sergio
Braga,Josefina A. P.
Lee,Maria Lúcia M.
Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemia
author_facet Delbuono,Elizabete
Maekawa,Yumi H.
Latorre,Maria do Rosário D. O.
Seber,Adriana
Petrilli,Antonio Sergio
Braga,Josefina A. P.
Lee,Maria Lúcia M.
author_sort Delbuono,Elizabete
title Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemia
title_short Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemia
title_full Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemia
title_fullStr Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemia
title_full_unstemmed Simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemia
title_sort simplified flow cytometric assay to detect minimal residual disease in childhood with acute lymphoblastic leukemia
description The detection of minimal residual disease (MRD) is an important prognostic factor in childhood acute lymphoblastic leukemia (ALL) providing crucial information on the response to treatment and risk of relapse. However, the high cost of these techniques restricts their use in countries with limited resources. Thus, we prospectively studied the use of flow cytometry (FC) with a simplified 3-color assay and a limited antibody panel to detect MRD in the bone marrow (BM) and peripheral blood (PB) of children with ALL. BM and PB samples from 40 children with ALL were analyzed on days (d) 14 and 28 during induction and in weeks 24-30 of maintenance therapy. Detectable MRD was defined as > 0.01% cells expressing the aberrant immunophenotype as characterized at diagnosis among total events in the sample. A total of 87% of the patients had an aberrant immunophenotype at diagnosis. On d14, 56% of the BM and 43% of the PB samples had detectable MRD. On d28, this decreased to 45% and 31%, respectively. The percentage of cells with the aberrant phenotype was similar in both BM and PB in T-ALL but about 10 times higher in the BM of patients with B-cell-precursor ALL. Moreover, MRD was detected in the BM of patients in complete morphological remission (44% on d14 and 39% on d28). MRD was not significantly associated to gender, age, initial white blood cell count or cell lineage. This FC assay is feasible, affordable and readily applicable to detect MRD in centers with limited resources.
publisher Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publishDate 2008
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842008000400010
work_keys_str_mv AT delbuonoelizabete simplifiedflowcytometricassaytodetectminimalresidualdiseaseinchildhoodwithacutelymphoblasticleukemia
AT maekawayumih simplifiedflowcytometricassaytodetectminimalresidualdiseaseinchildhoodwithacutelymphoblasticleukemia
AT latorremariadorosariodo simplifiedflowcytometricassaytodetectminimalresidualdiseaseinchildhoodwithacutelymphoblasticleukemia
AT seberadriana simplifiedflowcytometricassaytodetectminimalresidualdiseaseinchildhoodwithacutelymphoblasticleukemia
AT petrilliantoniosergio simplifiedflowcytometricassaytodetectminimalresidualdiseaseinchildhoodwithacutelymphoblasticleukemia
AT bragajosefinaap simplifiedflowcytometricassaytodetectminimalresidualdiseaseinchildhoodwithacutelymphoblasticleukemia
AT leemarialuciam simplifiedflowcytometricassaytodetectminimalresidualdiseaseinchildhoodwithacutelymphoblasticleukemia
_version_ 1756423440171008000